Findings from a recent study presented at the ESMO Sarcoma and Rare Cancer Congress indicate a substantial gap between precision oncology and real-world access to high-quality cancer treatments, with "only one in five patients with advanced rare cancers able to access treatment matched through individual molecular profiling." In addition, the study found very limited patient enrollment in clinical trials for rare cancer care; out of 304 patients recommended for clinical trials, only 6 were enrolled."
Click here to learn more.
Program details: Morfouace M, et al.Final analysis of the pan-European Arcagen study for molecular profiling and access to treatment for rare cancers: A joint EORTC-EURACAN initiative. ESMO Sarcoma and Rare Cancers Congress 2026 - Abstract 81MO
Only one in five patients with advanced rare cancers accessing molecularly matched treatment shows how far precision oncology still has to travel outside trial settings. The trial enrolment figure is just as stark — 6 out of 304 recommended patients actually enrolled. Access, referral pathways and awareness are the bottlenecks, not just science. Updates like this are regularly picked apart by the two onc docs, because rare cancers expose the equity gaps that larger tumour types can hide.
ReplyDeleteThe Arcagen numbers are a genuine wake-up call — only one in five advanced rare cancer patients getting molecularly matched treatment, and just 6 of 304 trial-recommended patients actually enrolled. For rare cancers, the bottleneck clearly is not the science but access, referral pathways, and awareness. A pan-European effort like this one deserves credit for measuring the gap honestly; you cannot fix what you do not quantify.
ReplyDelete